Glucotrack, Inc. Announces First-in-Human Trial Data for Continuous Blood Glucose Monitoring System to be Presented at 2025 ATTD Conference March 19, 2025 — 08:12 am EDT ...

Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management ...

The development of continuous glucose monitoring systems (either intermittently scanned systems or real-time systems) has enabled the monitoring of glucose levels without fingerstick testing. 5,6 ...

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 6 months in persons with diabetes age 18 and older.

The critical role of real-time, continuous blood glucose tracking Why the current CGM landscape needs a bold new solution Highlights from Glucotrack’s first-in-human clinical trial ...

Continuous Biomarker Monitoring Pioneer Proton Intelligence Inc Announces a $6.95 Million Seed Raise to Initiate Human Trials for Potassium Monitoring in Patients With Kidney Disease December 24 ...

Germantown, Maryland-based continuous glucose monitor developer Senseonics raised $20 million from existing investors Anthem Capital, Delphi Ventures, Greenspring Associates, Healthcare Ventures, and ...

In a trial evaluating a refractory chronic cough treatment, continuous cough monitoring allowed researchers access to an abundance of data and the treatment’s impact over time, according to a ...

Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology Trinity Biotech’s patented technology represents a paradigm ...

Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology Provided by GlobeNewswire Jan 28, 2025 12:20pm ...

Trinity Biotech’s Chief Technology Officer, Dr Gary Keating, added, “Our next phase of refinements, guided by this study’s positive results, will be tested in a second European pre-pivotal ...